Memantal in the treatment of moderate and severe Alzheimer’s disease

Written by Gavrilova S.I., Kolykhalov I.V., Ponomareva E.V.

  UDK: 616.894–053.8–085.214.31 | DOI: 10.17238/PmJ1609-1175.2019.1.23–28  Pages: 23–28 | Full text PDF | Open PDF 


Objective: The study objective is to analyze the effectiveness and safety of semi-annual therapy with the use of drug Memantal in patients with moderate and severe dementia cause by Alzheimer’s disease.
Methods: The study was performed on a group of 30 patients with moderate and severe Alzheimer’s disease aged from 55 to 84 y.o. A course of therapy with Memantal was given during 6 months. Treatment began with a dose of 5 mg, followed by an increase of 5 mg to achieve a therapeutic dose of 20 mg/day, 1 time in the morning. Evaluation of the effectiveness of therapy was carried out before the start of treatment and by the end of the 3rd and 6th months (MMSE, ADAS-Cog, NPI). The assessment of the impact on caregivers at home was performed according to RUD.
Results: A positive effect was achieved in 63.3 % of cases by the end of the course of therapy. A significant improvement in the cognitive functioning of patients compared to the baseline (MMSE and ADAS-Cog) was observed by the end of the first month of the study. Over the next three months, there was a slight increase in the positive effect on cognitive functioning. The dynamics of the indicators of the corresponding points of the NPI/NH scale confirmed that the use of Memantal contributes to a significant reduction in the stress load on caregivers.
Conclusions: The study showed that the use of Memantal in the conditions of semi-annual therapy in patients with Alzheimer›s disease at the stage of moderate and severe dementia improves not only cognitive and daily functioning, but also leads to the reduction of a wide range of non-cognitive mental disorders and thereby improves the quality of life of patients.

Links to authors:

S.I. Gavrilova, I.V. Kolykhalov, E.V. Ponomareva
Mental Health Research Center (34 Kashirskoye Shosse St. Moscow 115522 Russian Federation)

1. Belousov Yu.B., Zyryanov S.K., Belousov D.Yu. [et al.]. Clinical and economic aspects of the therapy of Alzheimer's disease in Russia // Good clinical practice. 2009. No. 1. Р. 3–28.
2. Gavrilova S.I., Kalyn Ya.B., Gherasimov N.P. [et al.]. A new form of specialized care for elderly people with dementia (organizational and pharmacoeconomic issues) // Journal of Social and Clinical Psychiatry. 2008. No. 2. Р. 36–40.
3. Gavrilova S.I., Kolykhalov I.V., Kulik A.S. [et al.]. Clinical experience of the use of Memantal in patients with moderate and severe Alzheimer's disease // Journal of Neurology and Psychiatry by S.S. Korsakov. 2016. Vol. 116, No. 2. Р. 52–57.
4. Kudashev V.A., Samsonov A.S. Compliance and quality of treatment of Alzheimer's disease by Memantal // Russian Medical Journal. Neurology. Psychiatry. 2014. No. 11. P. 1603–1607.
5. Lubov E.B. Pharmacoeconomic prognosis for long-term treatment of Alzheimer patients with akatinol (memantine) // Journal of Social and Clinical Psychiatry. 2011. No. 3. Р. 84–88.
6. Shiryaev O.Yu., Shapovalov D.L., Polozova T.M. [et al.]. A comparison of the efficacy and safety of Memantal and original memantine in the treatment of mild and moderate dementia in Alzheimer’s disease // Journal of Neurology and Psychiatry by S.S. Korsakov. 2015. Vol. 115, No. 10. Р. 61–66.
7. Bullock R. Efficacy and safety of memantine in moderate to severe Alzheimer's disease: The evidence to date // Alzheimer Disease & Associated Disorders. 2006. Vol. 20, No. 1. Р. 23–29.
8. Cummings J.L., Mega M., Gray K. [et al.]. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia // Neurology. 1994. Vol. 44, No. 12. Р. 2308–2314.
9. Farlow M.R., Cummings J.L. Effective pharmacologic management of Alzheimer disease // American Journal of Medicine. 2007. Vol. 120. P. 388–397.
10. Folstein M.F., Folstein S.E., McHugh P.R. Mini-Mental State. A practical method of grading the cognitive state of patients for the clinician // Journal of Psychiatry Research. 1975. No. 12. P. 189–198. 11 Grossberg G.T., Pejović V., Miller M.L., Graham S.M. Therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease // Dement. Geriatr. Cogn. Disord. 2009. Vol. 27, No. 2. P. 164–172.
12. Mahoney R., Regan C., Katona C. Anxiety and depression in family caregivers of people with Alzheimer disease: the LASER-AD study // Am. J. Geriatr. Psychiatrv. 2005. Vol. 13. P. 795–801.
13. Mohs R.C., Cohen L. Alzheimer’s Disease Assessment Scale (ADAS) // Psychopharmacology Bulletin. 1988. Vol. 24, No. 2. Р. 627–628.
14. Plosker G.L., Lyseng-Williamson K.A. Memantine: A pharmacoeconomic review of its use in moderate to severe Alzheimer's disease // Pharmacoeconomics. 2005. Vol. 23, No. 2. Р. 193–206.
15. Reisberg B., Doody R., Stöffler A. [et al.]. Memantine in moderateto- severe Alzheimer's disease // New England Journal of Medicine. 2003. Vol. 348. Р. 1333–1341.


Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.